Global Health Matters

18 September 2020 - By Thomas B. Cueni
Thomas Cueni, IFPMA Director General, spoke to BBC World Service Marketplace Morning Report about the efforts and challenges to produce and deliver a vaccine for COVID-19 Victoria Craig One of the keys to getting economies back to some form of normalcy is a vaccine. The US said that it could ...
Read More
18 September 2020 - By Thomas B. Cueni
Interview - Asahi TV Japan - Solidarity at the core of COVAX Facility Thomas Cueni, IFPMA Director General, spoke to Asahi TV in Japan on 18 September 2020 about COVAX and the importance of working together in order to guarantee a safe and effective vaccine in both richer and poorer ...
Read More
17 September 2020 - By Thomas B. Cueni
The biopharmaceutical industry has made addressing the pandemic its top priority, devoting its resources, expertise, know-how, and intellectual assets to developing potential treatments and vaccines at record speed, while committing to and engaging in unprecedented levels of international collaboration and coordination through initiatives such as ACT-A, ACTIV and CEPI to ensure equitable access to products being developed. ...
Read More
17 September 2020 - By Thomas B. Cueni
[embed]https://youtu.be/Aj6VSeWjaNo[/embed] Today I had the pleasure to participate in The New World Model, an online event on the future of industry, organised by the World Free Zones Organization. The event seeks to explore the different angles of the new industry business models likely to emerge in a post-pandemic landscape. I ...
Read More
17 September 2020 - By Thomas B. Cueni
This article first appeared in the Global Cause on the Infectious Diseases campaign. A printed publication was enclosed within every copy of New Scientist magazine and the content is available online on the Global Cause website. The campaign featured exclusive content from key thought leaders and industry voices about pharmaceutical ...
Read More
14 September 2020 - By Thomas B. Cueni
https://www.youtube.com/watch?v=-y3Ose3IeXQ&t=2142s On 3rd September, CEOs from five companies – Pfizer, Roche, MSD, Gilead, and Lilly took part in the latest IFPMA COVID-19 virtual media briefing dedicated to the on-going efforts to find a treatment for COVID-19. During the course of the pandemic, we have witnessed a remarkable show of solidarity, ...
Read More
9 September 2020 - By James Headen Pfitzer
With more than 20 IFPMA member companies, Access Accelerated is the largest collective industry effort to address inequities in non-communicable disease care. Access Accelerated recently launched its Year 3 report, chronicling the initiative’s collective efforts in 2019 to advance access to NCD prevention, treatment and care in low- and middle-income ...
Read More
8 September 2020 - By Thomas B. Cueni
Interview - BBC World News – COVID-19 vaccine manufacturers want to reassure the public and send a message to regulators 10 September 2020 – By Thomas B. Cueni [embed]https://youtu.be/0lwEAL7gU1M?t=127[/embed] Thomas Cueni, IFPMA Director General, spoke to BBC World New programme Outside Source, on 8 September 2020, about the need for ...
Read More
8 September 2020 - By Thomas B. Cueni
We all want a coronavirus vaccine. But no matter how urgently action is needed, it is imperative that the highest standards of quality, safety and efficacy are upheld. [...] We must prioritise thorough validation of the results of pre-clinical and clinical trials by independent expert bodies. There is no place ...
Read More
7 September 2020 - By Thomas B. Cueni
This oped was first published on Pharma Focus Asia on 2 September 2020. Reinforcing business integrity  There is great hope placed in science and in the biopharmaceutical’s industry efforts to find a solution that allows the world to “return to normal”. As the biopharmaceutical industry is at the heart of developing ...
Read More
30 July 2020 - By Thomas B. Cueni
On 24 July, Thomas Cueni, IFPMA Director General, joined Imogen Foulkes for the Inside Geneva podcast on  Swiss Info, to talk about the development, production and eventual distribution of COVID-19 vaccines. Their discussion highlighted the importance of broad-based collaborative efforts among all stakeholders as well as the vital necessity of ...
Read More
30 July 2020 - By Thomas B. Cueni
Published on Thomas Cueni’s LinkedIn profile. Last Wednesday, I sat down with @Chatham House’s @Emma Ross (moderator) and epidemiologist Professor @David L. Heymann to discuss the latest science and developments in the #COVID19 pandemic.   During the interview, we discussed how the pharmaceutical industry is collaborating on an unprecedented scale to develop ...
Read More
Photo courtesy of the Business Ethics for APEC SMEs Initiative
2 July 2020 - By Thomas B. Cueni
Authors: Dr. Jeff Blackmer, Mr. Thomas Cueni, Mr. Gaston Fernandez, Ms. Nancy Travis, Mr. Russell Williams The dual health and economic crisis resulting from COVID-19 has brought into sharp focus the importance of ethical business conduct. Emergency government measures, widespread economic and social disruption, as well as unscrupulous actors taking ...
Read More
4 June 2020 - By Thomas B. Cueni
Published on Thomas Cueni's LinkedIn profile. COVID-19 is not business as usual for any of us, especially not for the pharmaceutical industry. As we enter into the sixth month of the COVID-19 pandemic, I think it is no understatement to say that the global biopharmaceutical industry has been at the ...
Read More
2 June 2020 - By Thomas B. Cueni
Thomas Cueni, IFPMA Director General, spoke to BBC Sounds on 26 May on about the extent and importance of collaborations both between biopharmaceutical companies and with other stakeholders, notably universities and biotech companies to combat the COVID-19 crisis. At this stage, it is still impossible to know with certainty whether ...
Read More
1 2 3 11